The “drops first, everything else later” era is coming to an end. Dr Mark Chiang (Australia) shares his laser-first approach to glaucoma management: SLT to match first-line drop efficacy without the burden of daily medication, SubCyclo for patients who fail or cannot tolerate earlier treatments, and stents for the right surgical candidates.

The “drops first, everything else later” approach to glaucoma is being challenged. In this video, Prof. Gus Gazzard shares six-year LiGHT data showing that first-line SLT kept most eyes at target intraocular pressure without long-term drops, reduced the need for trabeculectomy, and delivered better visual field preservation compared with a drops-first approach.

In this interview, Prof. Gus Gazzard explains how SLT can be the first-line therapy for all open angle, glaucoma and ocular hypertension.

In this interview, Inder Paul Singh, MD, explains the interest of using SLT as first line therapy for glaucoma instead of medication and the impact on the ocular surface.
“SLT not only takes away the compliance issues that are so difficult for us but it actually addresses the pathology directly.”

The glaucoma medications used to control the IOP of refractive patients often add to the blurred vision experienced by these patients on a daily basis. This leaves the refractive surgeon with the frustrating task of correcting refractive error without being able to eliminate a key contributor to the problem. In this Video interview, Matthias Maus, MD, one of Germany’s leading refractive surgeons, addresses how SLT the role of SLT as an effective first-line glaucoma treatment for these patients, whilst eliminating the need for troublesome medications. Watch the video to learn more.